Careful choice of iodine contrast can spare sensitive kidneys

Article

Choosing an iso-osmolar dimeric contrast agent can reduce the risk of damage to kidneys in patients with diabetes or impaired renal function, according to a multinational study. Researchers in 17 centers evaluated serum creatinine output for 135

Choosing an iso-osmolar dimeric contrast agent can reduce the risk of damage to kidneys in patients with diabetes or impaired renal function, according to a multinational study.

Researchers in 17 centers evaluated serum creatinine output for 135 patients with impaired kidney function in a double-blinded study of iodixanol, an iso-osmolar nonionic dimeric contrast medium, and iohexol, a low-osmolar nonionic monomeric contrast medium.

Compared with a baseline reading, patients given iodixanol had an average peak increase of 11.2 mmol/L of creatinine during the next three days. For patients given iohexol, the increase was 48.2 mmol/L. Only 3% of patients given iodixanol crossed the threshold for nephrotoxicity, compared with 26.2% for iohexol patients.

The result, according to lead author Dr. Peter Aspelin of Huddinge University Hospital in Stockholm, was that patients given iodixanol were 11 times less likely to experience nephrotoxicity. The findings of the Nephrotoxicity in High Risk Patients study were published recently in the New England Journal of Medicine and presented at the European Congress of Radiology.

"The risk of nephropathy is already high in patients with diabetes mellitus," he said. "Iodixanol can lower that risk."

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.